Published in Blood on July 03, 2003
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood (2006) 1.46
BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A (2008) 1.34
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood (2008) 1.09
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J (2012) 0.94
Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood (2008) 0.90
Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci (2016) 0.86
Biphasic effect of curcumin on morphine tolerance: a preliminary evidence from cytokine/chemokine protein array analysis. Evid Based Complement Alternat Med (2011) 0.85
The Biology and Targeting of FLT3 in Pediatric Leukemia. Front Oncol (2014) 0.83
FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. Nagoya J Med Sci (2015) 0.83
The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. Blood Cancer J (2011) 0.80
Tyrphostin AG 1296 induces glioblastoma cell apoptosis in vitro and in vivo. Oncol Lett (2015) 0.75
NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia. Int J Mol Sci (2017) 0.75
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget (2016) 0.75
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol (2008) 3.12
Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology (2002) 2.85
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol (2010) 2.64
Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci (2007) 2.61
Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol (2009) 2.52
MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep (2006) 2.29
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood (2004) 2.27
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res (2007) 2.25
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol (2005) 2.24
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol (2007) 2.24
Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology (2009) 2.21
EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood (2011) 2.18
Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol (2002) 2.13
Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant (2006) 2.11
Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med (2012) 2.06
Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol (2003) 2.06
Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology (2003) 2.02
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol (2009) 2.00
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol (2012) 1.97
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood (2003) 1.87
Mutations in KaiA, a clock protein, extend the period of circadian rhythm in the cyanobacterium Synechococcus elongatus PCC 7942. Microbiology (2002) 1.83
Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol (2002) 1.82
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol (2008) 1.81
Integrin activation and matrix binding mediate cellular responses to mechanical stretch. J Biol Chem (2005) 1.80
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood (2011) 1.79
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol (2007) 1.79
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res (2004) 1.76
Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood (2008) 1.73
A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices. Am J Gastroenterol (2005) 1.68
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res (2006) 1.66
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood (2005) 1.66
Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension (2005) 1.62
Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med (2006) 1.62
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res (2010) 1.59
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene (2002) 1.56
Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood (2008) 1.53
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood (2002) 1.52
Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res (2003) 1.51
ACTN1 mutations cause congenital macrothrombocytopenia. Am J Hum Genet (2013) 1.49
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci (2012) 1.48
Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci (2009) 1.47
Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci (2010) 1.46
Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int (2010) 1.46
The first report of successful nasogastric Coca-Cola lavage treatment for bitter persimmon phytobezoars in Japan. Am J Gastroenterol (2003) 1.44
Nuclear targeting by the growth factor midkine. Mol Cell Biol (2002) 1.44
Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther (2010) 1.43
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology (2006) 1.43
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer (2005) 1.42
MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett (2011) 1.42
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res (2012) 1.42
Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett (2010) 1.42
Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J (2007) 1.41
Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res (2007) 1.40
Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med (2003) 1.40
Changes in repolarization properties with long-term cardiac memory modify dispersion of repolarization in patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2002) 1.40
Advances in the understanding of MYH9 disorders. Curr Opin Hematol (2010) 1.40
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol (2006) 1.40
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol (2014) 1.39
Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis (2004) 1.39
CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci (2006) 1.37
Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci (2008) 1.36
Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). J Virol (2002) 1.36
BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A (2008) 1.34
Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem (2007) 1.33
The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther (2006) 1.28
Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood (2002) 1.28
Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Commun (2004) 1.27
Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res (2005) 1.25
ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci (2011) 1.24
Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res (2004) 1.24
Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol (2004) 1.22